EUVIMEDEUVIMED entdecken
Open Access

Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?

Mohamed A Yakoub iD, Carla Saoud, Damon R Reed iD, Leonard Wexler iD, Emily Slotkin iD, William D Tap iD, Meera Hameed, Cristina R Antonescu iD

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-00909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von Mohamed A Yakoub und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Sarcoma, High-Throughput Nucleotide Sequencing, Translocation, Genetic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Translocation-associated sarcomas (TAS) represent a heterogeneous group of pathologic entities characterized by specific gene fusions and a low tumor mutational burden (TMB). Although RNA sequencing remains the hallmark molecular platform to establish the fusion type, targeted panel DNA next-generation sequencing (NGS) has been increasingly used in TAS to identify actionable alterations as well as potential mechanisms of resistance to therapy. MATERIALS AND METHODS We herein investigate sequential targeted DNA sequencing (Memorial Sloan Kettering Cancer Center—Integrated Mutation Profiling of Actionable Cancer Targets) in a large cohort of 108 TAS, spanning six most common subtypes, with available longitudinal sequencing. RESULTS Overall, 53% of cases acquired alterations (n = 122) compared with the initial testing, of which 33 (27%) were oncogenic/likely oncogenic. Only two of the five patients with >3 tests/each acquired oncogenic mutations. Overall, 21% of cases did not acquire alterations in any assay. Subsequent NGS was initiated after systemic treatment (93%) and disease progression (83%). The number of oncogenic acquired alterations did not correlate with histotype (mean 0.4/case). In sequential NGS, the mean mutation count, TMB, and fraction of genome altered were significantly higher ( P < .001, .04, and .03, respectively) compared with baseline. TP53 alteration was the most common acquired mutation (10%), being detected mostly in the subsequent assay. By contrast, other common alterations, such as STAG2 in Ewing sarcoma and gene amplifications in alveolar rhabdomyosarcoma, were detected at diagnosis. Although 27% of pathogenic alterations in the initial and 9% in the subsequent NGS were deemed as OncoKB levels 1-2 for other cancers, none were relevant for sarcomas. CONCLUSION The role of multiple NGS testing in the context of TAS remains undetermined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaHigh-Throughput Nucleotide SequencingTranslocation, GeneticHumansFemaleMaleAdultMiddle AgedMutationAdolescentChildYoung AdultAgedLongitudinal Studies

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Weill Cornell Medical College, New York, NY.

ORCID-Profile: Mohamed A Yakoub, Damon R Reed, Leonard Wexler, Emily Slotkin, William D Tap, Cristina R Antonescu

Förderung

  • NCI NIH HHS

Zitieren

APA

Yakoub, M. A., Saoud, C., Reed, D. R., Wexler, L., Slotkin, E., Tap, W. D., Hameed, M., & Antonescu, C. R. (2026). Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-00909

Vancouver

Yakoub MA, Saoud C, Reed DR, Wexler L, Slotkin E, Tap WD, et al. Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-00909

BibTeX
@article{Yakoub2026,
  author = {Yakoub, Mohamed A and Saoud, Carla and Reed, Damon R and Wexler, Leonard and Slotkin, Emily and Tap, William D and Hameed, Meera and Antonescu, Cristina R},
  title = {Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-00909}
}
Kostenlos starten →